Carbamodithioic acid, (4-pyridinylmethyl)- | 45957-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Carbamodithioic acid, (4-pyridinylmethyl)-
• 英文别名: pyridin-4-ylmethylcarbamodithioic acid
• CAS: 45957-43-5
• 化学式: C₇H₈N₂S₂
• 分子量: 184.3
• InChiKey: RVCVCIOONPYRBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CARBONIC ANHYDRASE INHIBITOR COMPRISING A DITHIOCARBAMATE<br/>[FR] INHIBITEURS D'ANHYDRASE CARBONIQUE
  申请人：UNI I OSLO

  公开号：WO2013050426A1

  公开（公告）日：2013-04-11

  A carbonic anhydrase inhibitor which comprises a compound of general formula: R1R2N-CS2-M+ for use in the treatment of microbial infection, eye disease or cancer; wherein R1 and R2 are each independently selected from H or an organic substituent, or together form a ring, and optionally contain one or more heteroatoms; wherein R and R2 together comprise at least 5 carbon atoms or at least 2 carbon atoms and a heteroatom, or R2 comprises at least 4 carbon atoms; and wherein M+ comprises a monovalent cation.

  一种碳酸酐酶抑制剂，包括通用结构式的化合物：R1R2N-CS2-M+，用于治疗微生物感染、眼部疾病或癌症；其中R1和R2分别独立地选自H或有机取代基，或者一起形成一个环，并且可选地包含一个或多个杂原子；其中R和R2一起至少包含5个碳原子或至少2个碳原子和一个杂原子，或者R2至少包含4个碳原子；M+包括一价阳离子。
• HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
  申请人：Peking University

  公开号：EP2562157A1

  公开（公告）日：2013-02-27

  Heteroaryl (alkyl) dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer.

  本发明公开了通式(I)代表的杂芳基（烷基）二硫代氨基甲酸酯化合物或它们的药学上可接受的盐、它们的制备方法以及它们在制备抗肿瘤药物中的用途，其中每个所述取代基的定义如说明书中所述。 这些化合物是新的酪氨酸激酶抑制剂，可用作抗肿瘤药物，优选用于制备治疗乳腺癌、肝癌、非小细胞肺癌、胃癌、结肠癌、白血病或鼻癌的药物。
• Parkin ligase activation methods and compositions
  申请人：An2H Discovery Limited

  公开号：US10155936B2

  公开（公告）日：2018-12-18

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.

  本发明涉及通过向有需要的受试者施用治疗有效量的破坏至少一个Parkin连接酶锌指的化合物来激活Parkin连接酶的方法和组合物。本发明还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。
• PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS
  申请人：An2H Discovery Limited

  公开号：US20160160205A1

  公开（公告）日：2016-06-09

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.